key: cord-0698181-8snyy5zp
authors: Diallo, Alhassane; Carlos-Bolumbu, Miguel; Traoré, Marie; Diallo, Mamadou Hassimiou; Jedrecy, Christophe
title: An updated systematic review and network meta-analysis of 25 randomized trials assessing the efficacy and safety of treatments in COVID-19 disease
date: 2021-02-03
journal: J Public Health Res
DOI: 10.4081/jphr.2021.1945
sha: 5c9416f9c2eb2d655c215ddad86f2c726eee7f76
doc_id: 698181
cord_uid: 8snyy5zp

To date, there is no definite effective treatment for the COVID- 19 pandemic. We performed an update network meta-analysis to compare and rank COVID-19 treatments according to their efficacy and safety. Literature search was performed from MEDLINE and CENTRAL databases from inception to September 5, 2020. Randomized clinical trials (RCTs) which compared the effect of any pharmacological drugs versus standard care or placebo 28-day after hospitalization in adult patients with COVID-19 disease were included. Risk ratio (RR) and 95% CI were calculated for 28-day all-cause mortality, clinical improvement, any adverse event (AEs), and viral clearance. A total of 25 RCTs, evaluating 17 different treatments, and 11,597 participants were analyzed. Remdesivir for 10- day compared to standard care (RR 0.69, 95% CI [0.48–0.99]), and a low dose compared to a high dose of HCQ (0.38, [0.17–0.89]) were associated with a lower risk of death. A total of 2,766 patients experienced clinical improvement, a 5-day course of remdesivir was associated with a higher frequency of clinical improvement compared to standard care (RR 1.21, 95% CI [1.00–1.47]). Compared to standard care, remdesivir for both 5 and 10 days, lopinavir/ritonavir, and dexamethasone reduced the risk of any severe AEs by 52% (0.48, 0.34–0.67), 24% (0.77, 0.63–0.92), 40% (0.60, 0.37–0.98), and 50% (0.50, 0.25–0.98) respectively. In this study of hospitalized patients with COVID-19, administration of remdesivir for 10-day compared to standard care was associated with lower 28-day all-cause mortality and serious AEs, and higher clinical improvement rate.

Despite more than 28 million cases and 900,000 deaths in early September caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, no definite effective treatment is available. 1 The urgency of this situation accelerated randomized trials of many repurposed drugs that had been shown to be effective in vitro or in or the therapeutic experience with SARS-CoV-1, and Middle East respiratory syndrome (MERS)-CoV infection. 2 In this context, numerous meta-analyzes were quickly carried out, in particular on the efficacy of hydroxychloroquine (HCQ). Data from Million et al. 3 indicated the effectiveness of HCQ in reducing mortality in COVID-19 disease, while those of Singh et al. 4 and Fiolet et al. 5 concluded that HCQ was ineffective.

A recent prospective meta-analysis of seven clinical trials involving 1,703 critically ill patients with COVID-19 reported the benefit of routine administration of corticosteroids, compared with usual care or placebo, in to reducing 28-day all-cause mortality based only on the fixed-effect model. 6 Overall, routine administration of corticosteroids is associated with a 34% reduction in mortality (summary OR, 0.66 [95%CI, 0.53-0.82]), and among corticosteroid drugs, only dexamethasone was beneficial (0.64 [0.50-0.82]). In the subgroup analysis, the greatest benefit of systematic corticosteroids was observed in patients who were not receiving vasoactive drugs (0.55 [0.34-0.88]) or invasive mechanical ventilation at randomization (0.41 [0.19-0.88]).

As there is no recommended treatment or vaccine to contain the disease to date, identifying the most effective treatment is an urgent medical need. To summarize data on promising treatments against COVID-19, we conducted a preliminary network metaanalysis (NMA) based on 14 randomized controlled trials (RCTs) evaluating 11 different treatments among 2,898 patients. 7

The current COVID-19 pandemic is the largest and deadliest coronavirus pandemic in history, leading to considerable global public health problems. To date more than 28 million cases and 900,000 deaths have been reported. This is an update of our previous systematic review and network meta-analysis to compare and rank COVID-19 treatments. Available data indicate that in hospitalized patients with SARS-CoV-2 infection, administration of remdesivir compared to standard care and low dose of HCQ compared to high dose were associated with lower risk of 28-day all-cause mortality. In the absence of compelling contraindication, a remdesivir regimen should be part of standard care for inpatients with [Journal of Public Health Research 2021; 10 We found no difference between treatments in terms of reduced 28-day all-cause mortality. The aim of this update network meta-analysis of randomized trials was to compare and rank the efficacy and safety of treatments tested in patients with SARS-CoV-2 virus.

In our previous report, 7 search through MEDLINE and Cochrane library (CENTRAL) was performed from inception to June 30, 2020 and it identified 14 RCTs published in any language. Then, from July 1 to September 5, 2020, 11 additional RCTs were found and included in the current updated network meta-analysis. Data were collected as studies were identified; the latest date for this search was September 5, 2020. We included RCTs that compared in adult patients with COVID-19 (P) any pharmacologic drug (I) versus standard care or placebo (C) to evaluate both efficacy (mortality, clinical improvement, viral clearance) and safety (adverse event and serious adverse event) (O) 28-day (T) after hospitalization (S). Trials in which participant were non-randomly assigned to SARS-CoV-2 treatment were excluded. Using the search terms listed in the Supplementary Method, AD and MT identified all relevant studies, then independently reviewed their full texts, and in case of disagreement, differences were resolved through arbitration by another author (MCB). Extracted data included: first author name and year of publication, country, RCTs design, study follow-up, age (mean), proportion of male participants, treatment and dosing information, sample size, study sponsorship, proportion or number of participants with clinical improvement, all-cause mortality, and adverse events. The study protocol number is CRD42020176977 (PROSPERO).

We considered any pharmacological drugs tested to evaluate their efficacy and safety in patients infected with SARS-CoV-2. For randomized trials, patients were defined as receiving intervention or control if they were randomly allocated to receive either treatment. Almost all patients received supportive care according to the standard care at the trial site.

The primary outcome was 28-day all-cause mortality. Secondary outcomes were clinical improvement within 28-day after randomization, any reported Adverse Events (AEs), severe AEs, and viral clearance rate (negative conversion rate). Clinical improvement was defined as patient discharge or a reduction of 2 points on a 7-point disease severity scale. As these secondary outcomes were evaluated at different time-points across studies, we chose to consider only the latest in each trial.

The original clinical trials were described using summary table of study characteristics and forest plot. The Revised tool for Risk of Bias in randomized trials (Rob2 tool) 8 was used to assess the risk of bias and to generate its number? We opted for a frequentist approach to compare the efficacy and safety of the treatments tested using a random-effects network meta-analysis (NMA) for binary endpoint. Summary estimates were reported as risk ratio (RR) with their reported 95% confidence intervals. For clinical improvement and decreased viral load, beneficial effects are described by RRs >1, while for 28-day mortality and AEs, beneficial effects are described by RRs <1. To display the relative efficacy and safety outcomes of all available pairwise comparisons between treatments, league tables were used. To choose the preferred regimen, the P-score ranging from 0 (worse treatment) to 1 (best treatment) was computed for each treatment, then the treatment with a higher P-score was selected as better than the competing treatment. Heterogeneity and inconsistency were quantified using the global Q test proposed by Rucker. 9 The Q statistic is the sum of statistic for heterogeneity, which represent the proportion of total variation in study estimates (within-designs), and a statistic for inconsistency (between-designs), which represents the variability of treatment effect between direct and indirect comparisons at the meta-analytic level. To visualize and identify the nodes of single-design inconsistency, we used a network heat plot. Consistency between direct and indirect comparisons was checked using the so-called node-splitting. To confirm or deny the effect of any corticosteroid on 28-day all-cause mortality reported in the WHO prospective meta-analysis, 6 we performed one non-prespecified sensitivity analysis by considering any routine corticosteroid as a single treatment (combining dexamethasone, hydrocortisone and methylprednisolone). All analyses were performed using R package 'netmeta'; 9 P-values <0.05 were considered significant for the difference between treatments.

The initial search through all database identified 1,042 citations, of which 402 were screened by title and abstract after removing duplicates. Of 38 full-text citations reviewed, 25 RCTs 6,10-31 that met the inclusion criteria were finally included in the quantitative network meta-analysis ( Figure 1 ). These 25 RCTs (two phase 2 and five blinded) included a total of 11,597 patients infect-Systematic Reviews and Meta-Analysis ed by the SARS-CoV-2 with mean ages ranging from 29.7 to 70 years; 7,363 (62.3%) were men; they were followed for 6 to 28 days (Table 1) . Comorbidities were present in 4,579 (39.0%) patients, the most common being diabetes (2,818; 24.0%) and hypertension (1,761; 15.0%).

The methodological quality of included RCTs is shown in Supplementary Figures 1 and 2 . Overall, the risk of bias was low in nine RCTs, moderate in four, and high in the remaining RCT. A higher risk of attrition bias (incomplete outcome data), performance bias (blinding participants and personnel), and selection bias (allocation concealment) occurred in 6, 6, and 1 of the 25 RCTs, respectively.

All-cause mortality data were reported in 18 trials involving 14 treatments and 22 comparisons. A total of 2,228/10,880 (20.4%) patients died within 28 days of randomization, and ruxolitinib (5 mg twice a day) was ranked as the best option with an 83% probability (P-score 0.83) to be associated with a lower risk of death. Table 1) . Likewise, no significant differences were found between direct and indirect comparisons of treatment estimates or evidence of publication bias according to the comparisonadjusted funnel plot ( Supplementary Figures 3 and 4 ).

Clinical improvement data were reported in 17 trials involving 13 treatments and 23 comparisons. Among the 4,317 participants in whom clinical status was evaluated, 2,766 (64.1%) experienced clinical improvement within 28 days after randomization. Treatment with Ruxolitinib 5 mg twice daily was ranked with a high probability of clinical improvement at 28 days (P-score 0.78) to be the best one. Except between remdesivir and standard care, no significance differences between treatments were found from pairwise comparisons (Figure 3 and Supplementary Table 2) . RR for remdesivir 100 mg once daily for 5 days compared with standard care was 1.21 (95% CI 1.00-1.47).

Viral clearance rate was assessed in 7 10, 11, 14, 15, [17] [18] [19] RCTs involving 6 treatments and 9 comparisons. The use of convalescent plasma was associated with higher viral clearance rate (P-score 1.00) compared to arbidol, standard care, HCQ, lopinavir/ritonavir, and 10-day remdesivir. 

Concerning safety outcomes, the network meta-analysis was performed in 21 RCTs, involving 17 treatments and 27 comparisons. Figure 2 shows the network for adverse event captured by the SARS-CoV-2 treatment, and the corresponding pairwise comparisons are summarized in Supplementary Table 4 . A total of 1,828/5,077 (36.0%) adverse events were reported at the end of treatment. Dexamethasone was ranked as the best option with a probability of 90% (P-score 0.90) of being associated with a lower risk of any AEs. Except the use of convalescent plasma and the association HCQ plus azithromycin (HCQ+AZT), the remaining treatments were significantly associated with a lower risk of any AEs as compared to colchicine (Supplementary Table 4 ). The corresponding risk reductions ranged from 48% to 82%. In addition, we found that dexamethasone, arbidol, low dose of HCQ (400 mg), and standard care (Figure 3 ) reduced the risk of any AEs by 66% (0.34, 0.13-0.88), 62% (0.38, 0.14-1.00), 50% (0.30, 0.14-0.83), and 27% (0.73, 0.55-0.99) when compared with HCQ. The corresponding reduction rate of any AEs when compared with HCQ plus azithromycin (HCQ+AZT) was 69% (0.31, 0.12-0.83) for Table 4 ).

A total of 598 serious adverse events were recorded from 15 RCTs involving 19 comparisons of 11 different treatments. A combination of lopinavir/ritonavir and ribavirin was associated with a risk reduction for any severe AEs with a probability 86% (P-score 0.86). Compared to standard care, remdesivir for both 5 and 10 days, lopinavir/ritonavir, and dexamethasone reduced the risk of any severe AEs by 52% (0.48, 0.34-0.67), 24% (0.77, 0.63-0.92), 40% (0.60, 0.37-0.98), and 50% (0.50, 0.25-0.98) respectively ( Figure 3) . Moreover, we found that the short exposition of remdesivir (5 days) reduced the risk of any severe AEs by 37% (0.63, 0.46-0.85) compared with the long exposition (10 days), and by 50% (0.50, 0.35-0.71) compared to methylprednisolone (Supplementary Table 5 ).

In sensitivity analysis, after considering any systematic corticosteroids as a single treatment, ruxolitinib (P-score 0.82) remained the best option to reduce all-cause mortality 28 days after randomization (Supplementary Table 6 ). Compared with standard care, both 5-day and 10-day courses of remdesivir and routine corticosteroids were associated with lower 28-day all-cause mortality. The specific relative reductions were as follows: for 5-day remdesivir, 52% reduction (0.48, 0.23-0.98); for 10-day remdesivir, 34% reduction (0.66, 0.45-0.96); and for routine corticosteroids, 15% reduction (0.85, 0.76-0.95). In addition, a low dose of HCQ reduced by 72% (0. 28 .1%] respectively), mainly due to significant between-design heterogeneity (AEs and clinical improvement). These finding were supported by the heat plot displayed in the Supplementary Figures 5 to 9 ).

One month after our previously published report, 7 , we performed an update network meta-analysis of 25 RCTs that included 11,597 patients randomly assigned to 17 different treatments against SARS-CoV-2. Compared to standard care, the administration of a 10-day course of remdesivir was associated with a lower all-cause mortality and serious adverse event at 28 day, and a higher rate of clinical improvement. In addition, we found that compared to high dose, low dose of HCQ was associated with a lower 28-day mortality. Convalescent plasma was associated with a high rate of viral clearance, and dexamethasone and lopinavir/ritonavir were associated with a low risk of serious adverse event.

The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group 6 reported the benefit of administration of systemic corticosteroids to reduce 28-day mortality by 34% in COVID-19 patients compared to standard care. However, when corticosteroid types were considered, a benefit was only observed in patients receiving dexamethasone (0.64, 0.50-0.82). These findings were based on a fixed effect-model, while those on the random-effect model were not significant. After considering all avail-able option for COVID-19 management, there was no evidence of a benefit of dexamethasone or hydrocortisone or methylprednisolone in reducing 28-day all-cause mortality (Supplementary  Table 6 ). However, all corticosteroids were considered as a single treatment, we found that administration of systematic corticosteroids reduced 28-day mortality by 15%. This is similar in magnitude to the data reported in the RECOVERY trial 28 in which dexamethasone reduced by 17% (0.83, 0.75-0.93) 28-day mortality compared to standard care.

Most of the treatments being compared were tested in hospitalized patient with severe condition. At the time these trials were designed, little was known about the physiopathology of COVID-19. To date, we believed that the optimal management of COVID-19 could take in to account the stage of the disease. First, we found that the use of convalescent plasma increases viral clearance, suggesting that convalescent plasma may be beneficial for the early phase of the disease. Second, given the results of a 10-day course of remdesivir on 28-day all-cause mortality and clinical improvement rate, in the absence of contraindication, its use could benefit patient before the onset of a respiratory failure. Finally, as proposed by the WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, in the absence of compelling contraindication, a corticosteroid regimen should be a component of standard care for critically ill patients with COVID-19.

The place of hydroxychloroquine in the therapeutic panel in patients with COVID-19 is unclear. We found that low dose of hydroxychloroquine (400 mg/d for 5 days) was associated with lower 28-day all-cause mortality and serious adverse event as compared to high dose, but with no benefit compared to usual care. These findings are in line with a recent systematic review of 32 studies (29, 192 participants) on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19. The authors concluded that the available evidence from biased, moderate-risk studies did not suggest any benefit of CQ/HCQ in terms of mortality in hospitalized patients with COVID-19 compared to standard care. 37 Nevertheless, available date on the efficacy of HCQ are conflicting. 32-36 While Million et al. 3 shows that patients who received HCQ had a 68% (0.32, 0.19-0.52) reduction in the risk of death compared to those without HCQ, Singh 4 and Fiolet 5 indicate the complete opposite with an increase in mortality for patients treated by HCQ. Furthermore, the Canadian trial on the prophylactic role of HCQ shows that hydroxychloroquine did not prevent illness compatible with COVID-19 or confirmed infection when used as postexposure prophylaxis within 4 days after exposure to COVID-19. 38 Although our study provides the most recent evidence to date on the comparative efficacy and safety of available treatments against SARS-CoV-2, these findings should be interpreted with caution. We are aware that the majority of pharmacological drugs classified as the best options for clinical improvement, all-cause mortality or safety concerns have only been tested once, and further data are needed to replicate these results. To date several trials registered in ClinicalTrials.gov databases are ongoing, and results are expected in the coming months. When all ongoing trials are published, an update of this work will be necessary to draw definitive conclusions about the efficacy and safety of the treatments tested against SAR-CoV-2.

This study has several limitations. First, the small number of RCTs included in the network meta-analysis negating the possibility of performing subgroup analyzes according to studies characteristics (design, follow-up, sample size, endpoint assessment, patient characteristics, or risk of bias). Second, the different end-points used to assess of efficacy and safety outcomes may potentially influence the results. Third, we did not find RCT about asymptomatic or pauci-symptomatic patients with positive SARS-CoV-2 test, in whom the standard of care is observation and quarantine. 38 In addition, the majority of RCT included a large number of patients who have satisfactory clinical parameters, like SOFA 1, oxygen saturation 97.7%, 1 ) or those not needing oxygen supplementation. 28 

In this network meta-analysis of 25 randomized trials against COVID-19 disease, the administration of a 10-day course of remdesivir was associated with lower 28-day all-cause mortality and serious adverse event, and higher clinical improvement rate compared to standard care. Colchicine and high dose of HCQ raised more safety concerns compared to dexamethasone, arbidol, favipiravir, low dose of HCQ (400 mg), remdesivir for both 5 and 10 days, and standard of care. As the pandemic is still ongoing, definitive conclusion will be drawn taking into account the results of ongoing and future studies. Nevertheless, these findings have implications for the design and management of future COVID-19 clinical trials.

COVID-19 Dashboard by the Center for Systems Science and Engineering

Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current therapeutic options and potential targets for novel therapies

Clinical efficacy of chloroquine derivatives in COVID-19 infection: Comparative meta-analysis between the big data and the real world

Hydroxychloroquine in patients with COVID-19: A systematic review and meta-analysis

Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis

Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19: A meta-analysis

Efficacy and safety data of treatments for novel coronavirus pneumonia (SARS-Cov-2): A systematic review and network meta-analysis of randomized trials

RoB 2: A revised tool for assessing risk of bias in randomized trials

Meta-analysis with R

Treating COVID-19 with chloroquine

Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial

Favipiravir versus arbidol for COVID-19: A randomized clinical trial

An exploratory randomized controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI)

Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A randomized clinical trial

Remdesivir for 5 or 10 days in patients with severe Covid-19

Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open

Systematic Reviews and Meta-Analysis label, randomised controlled trial

A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection: A randomized clinical trial

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Hydroxychloroquine with or without azithromycin in mild-tomoderate Covid-19

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, singleblind, randomized controlled trial

Remdesivir for the treatment of Covid-19 -Preliminary report

Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: A randomized clinical trial

Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia: results from a randomized controlled trial

Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: The CoDEX randomized clinical trial

Dexamethasone in hospitalized patients with Covid-19 -Preliminary report

Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: A randomized clinical trial

Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: The REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial

Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: The GRECCO-19 randomized clinical trial

Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19

Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in

Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data

Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France

Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine /azithromycin and other regimens in Marseille, France: A retrospective analysis

Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19

A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19